Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors
Clinical Transplantation · 2026
DOI: 10.1111/ctr.70439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2026. Verfasst von Ye In Christopher Kwon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic Surgery, Department of Surgery, Pauley Heart Center, School of Medicine, Virginia Commonwealth University, Richmond, Virgi…. Hauptthemen laut MEDLINE: Heart Transplantation, COVID-19, Tissue Donors, Graft Rejection. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
As COVID‐19 becomes endemic, evaluating COVID‐19+ donors for heart transplantation (HT) remains important. We assessed long‐term outcomes using national data and propensity‐matched analysis.
Methods
All adults (>18 years) undergoing HT between 4/2020 and 9/2024 were identified in the UNOS database. They were stratified into COVID‐19+ versus –, defined by either a positive nucleic acid or antigen test within 7 days of HT. Groups were then 3:1 nearest propensity score matched. Survival was estimated by the Kaplan–Meier method. Mortality risk was assessed using Cox regression models.
Results
A total of 879 recipients of COVID‐19– hearts were matched with 293 recipients of COVID‐19+ hearts. We found no significant differences in 3‐year landmark survival between cohorts ( p = 0.23). Rates of acute rejection ( p = 0.15), length of hospital stay (LOS) ( p > 0.9), and postoperative stroke ( p = 0.53) did not differ significantly between groups. However, dialysis (17% vs. 12%, p = 0.04) and primary graft dysfunction rates at 24‐h post‐HT were significantly higher in COVID‐19+ heart recipients (5.5% vs. 1.8%, p = 0.01). Donor COVID‐19+ status was not significantly associated with mortality risk (HR 1.01, p = 0.66). COVID‐19+ donor HTs in recent years (2022–2024) were associated with decreased mortality risk (HR 0.82, p = 0.02), rates of acute rejection ( p < 0.001), LOS ( p = 0.01), and dialysis (18% vs. 8.9%, p = 0.03).
Conclusions
COVID‐19+ hearts demonstrate adequate long‐term outcomes, particularly in recent years. Future studies should assess the impact of donor vaccination to optimize survival benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiothoracic Surgery, Department of Surgery, Pauley Heart Center, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
- School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
- Department of Biostatistics, School of Population Health, Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID-Profile: Ye In Christopher Kwon, David T Zhu, Alan Lai, Matthew Ambrosio, Zachary Fitch, Josue Chery, Vigneshwar Kasirajan, Zubair A Hashmi
Zitieren
APA
Kwon, Y. I. C., Bao, B., Guiry, J., Zhu, D. T., Lai, A., Ambrosio, M., Kesari, A., Patel, J., Fitch, Z., Chery, J., Nicolato, P., Kasirajan, V., & Hashmi, Z. A. (2026). Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors. Clinical Transplantation. https://doi.org/10.1111/ctr.70439
Vancouver
Kwon YIC, Bao B, Guiry J, Zhu DT, Lai A, Ambrosio M, et al. Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors. Clinical Transplantation. 2026. doi:10.1111/ctr.70439
BibTeX
@article{Kwon2026,
author = {Kwon, Ye In Christopher and Bao, Brian and Guiry, Jack and Zhu, David T and Lai, Alan and Ambrosio, Matthew and Kesari, Aditya and Patel, Jay and Fitch, Zachary and Chery, Josue and Nicolato, Patricia and Kasirajan, Vigneshwar and Hashmi, Zubair A},
title = {Evolving Long‐Term Outcomes of Heart Transplantation Using COVID‐19 Positive Donors},
journal = {Clinical Transplantation},
year = {2026},
doi = {10.1111/ctr.70439}
}
EUVIMED